Previous work showed that glycemic control can be improved when rtCGM is used in conjunction with basal insulin therapy in patients with T2D [8], with significant improvement in satisfaction scores and growing acceptance and comfort with rtCGM technology over time. The gene discussed is INS; the disease is type 2 diabetes mellitus.